TPP as a Leadership Tool: Aligning Evidence, Labeling, and Company Strategy
A biotech is eighteen months into a Phase II program. The TPP was updated once after the first data readout and has not been opened since. The clinical team is optimizing around the primary endpoint. CMC is making manufacturing decisions based on the production timeline. The nonclinical team is planning studies based on phase of development. Commercial is building the market model around an indication scope no one has pressure-tested against what the evidence will actually support. None of these teams are making bad decisions. They are making decisions without a shared reference point.
The TPP exists in most programs, but the strategic function it was designed to serve is rarely what it actually performs. Without it, misalignment accumulates quietly across clinical, CMC, and commercial functions until the program is too far along to correct it without significant cost.
The TPP, when used as intended, is the document that forces the hardest strategic conversations in drug development: what the product will claim, what evidence will support those claims, and whether the development program is designed to deliver on the labeling ambition. When it is treated as a regulatory deliverable rather than a leadership instrument, those conversations do not happen.
The consequences are predictable, expensive, and almost entirely avoidable.
In brief: The TPP was designed to be a living instrument that holds clinical, CMC, and commercial decisions against a shared labeling ambition. In most programs it is drafted, filed, and forgotten. The cost of that rarely shows up where the decision was made; it tends to surface at submission, when the evidence package is fixed and the gap between what the program proved and what the label needs to say is no longer closeable.
What the FDA Intended the TPP to do
FDA's 2007 draft guidance on the Target Product Profile describes it explicitly as "a strategic development process tool." The agency did not frame the TPP as a submission requirement or a regulatory deliverable. It framed it as a tool that should evolve throughout development and serve as the bridge between the labeling a company is working toward and the development activities designed to support that labeling. The key phrase from the guidance is that the TPP "provides a format for discussions between the sponsor and FDA", a living document that shapes the conversation between the company and the agency as the program evolves.
Most companies draft the TPP and do not revisit and revise along the development journey. The TPP was intended to become a record of what was discussed to connect trajectory of the product development. Clinical decisions are made. CMC commitments are locked. The competitive landscape shifts. If the TPP does not change, because no one is using it as the reference point it was designed to be development strategy becomes misaligned.
The gap between FDA's intent and the way most companies use it is where the strategic value of the TPP gets lost.
The practical consequence of that choice is a program where evidence, labeling, and strategy drift apart so gradually that no one notices until a regulatory submission forces the question.
How a TPP Built for the FDA Creates Problems in Europe
The FDA and the EMA have different labeling philosophies, different evidence standards, and different approved indications for the same products. For programs with global ambitions, that divergence needs to be built into the TPP from the start.
A TPP built around FDA's labeling framework will embed assumptions that do not translate directly to the EMA. EMA's Summary of Product Characteristics (SmPC) follows a different structure and reflects a different evidentiary logic. The SmPC is not a reformatted version of the FDA label. It is a different document, built on a different assessment framework, and the evidence required to support it may differ in ways that are not obvious from the FDA-facing TPP alone.
Beyond the regulatory label itself, EMA approval now feeds directly into the EU Joint Clinical Assessment process under the Health Technology Assessment (HTA) Regulation. The evidence a program generates needs to satisfy not just EMA's approval standard but the comparative effectiveness questions that HTA bodies will ask. Questions about comparators, patient subpopulations, and clinical relevance that may not have been part of the FDA-facing evidence strategy. A TPP that does not account for these downstream evidence requirements will leave gaps in the evidence package that are expensive to close after the clinical program is locked.
A global TPP needs to be built with both regulatory environments in view from the start. That requires regulatory leadership with the depth to hold both lenses simultaneously.
Where the Target Product Profile Falls Short in Global Submissions
Most biotechs use the TPP as a regulatory document. That is exactly the problem.
- Clinical teams set endpoints based on scientific rationale and trial feasibility.
- CMC teams make manufacturing decisions based on technical and timeline constraints.
- Commercial teams build market models based on competitive landscape and payer expectations.
Each of these functions is making decisions that have direct implications for TPP and yet it is often absent from those conversations.
The result is a TPP that reflects the regulatory affairs team's best current view of the label, disconnected from the actual trajectory of the program. When the clinical data comes in and the evidence package is assembled for submission, the gap between the TPP's labeling ambition and what the data can support becomes visible. By then, the clinical program is complete and the options for closing the gap are limited to adjusting the labeling ambition downward to match the evidence rather than having designed the evidence to match the labeling ambition from the start.
The TPP should be the document that a cross-functional leadership team reviews when any major development decision is being made, to ask whether the decision being made is consistent with the labeling ambition the company has committed to. When it is not, the misalignment compounds silently until submission makes it visible.
What it Looks Like When the TPP Functions as a Leadership Tool
When the TPP functions as a leadership tool, it is a living document reviewed at cross-functional leadership meetings, not just regulatory affairs team meetings. Every major development decision is held against the labeling ambition it represents. When the clinical team proposes a protocol amendment, the question is whether the amendment is consistent with the TPP. When the CMC team makes a manufacturing decision, the question is whether it supports the quality attributes the label will need to reflect.
Using the TPP as a leadership tool requires more than updating a document. It requires someone with the authority to bring it into rooms where it has not previously been, and to hold the labeling ambition as a fixed reference point when functions are pulling in different directions.
A TPP that holds both regulatory environments in view from the start forces the evidence strategy to account for both agencies' expectations before the clinical program is designed. That discipline also changes the quality of agency interactions, when a company enters a pre-IND meeting or a scientific advice procedure with a TPP that has been pressure-tested across functions and regulatory environments, the questions it asks are sharper and the agency's feedback is more actionable.
Most biotechs have a Target Product Profile. The question is whether the leadership team is using it as the strategic instrument it was designed to be. The companies that treat it as a strategic instrument arrive at submission with an evidence package that supports the label they need, in both regulatory environments, without the late-stage rework that delays timelines and erodes confidence in the program. SSI Strategy works with biotech teams to build that discipline.
If your TPP is not actively shaping cross-functional decisions in your program, explore how SSI helps biotech teams use regulatory strategy as a leadership tool.
Related reading
Explore our Regulatory Offering:
Regulatory Strategy & Leadership
Continue reading:
Why Regulatory Belongs in the C-Suite
When Is It Time for a Chief Regulatory Officer?
Risk-Based Regulatory Strategy
The Regulatory Agency Interaction Plan
